Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Corporate
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
25 October 2017
GenSight Biologics Appoints Barrett Katz as Chief Medical Officer
04 October 2017
GenSight Biologics to Attend Chardan Gene Therapy Conference
28 July 2017
GenSight Biologics Reports Interim Financial Results for the First Half of 2017
23 June 2017
Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics
22 June 2017
GenSight Biologics launches a capital increase of approximately €20 million
03 May 2017
GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer
28 April 2017
GenSight Biologics Announces the Filing of its 2016 Registration Document
19 April 2017
GenSight Biologics to Attend Upcoming Investor Conferences
13 March 2017
GenSight Biologics Reports Full Year 2016 Financial Results
13 October 2016
GenSight Biologics reports its cash position as of September 30, 2016
View previous 9 articles
1
…
10
11
12
13
14
15
16
View next 9 articles
Go back to the page of the page